Sublingual tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a randomized, placebo-controlled crossover study

British Journal of Dermatology 2026 Open access

Read full text
Authors: Nicholas H. B. Schräder, José C. Duipmans, Peter Sörös, Karin M Vermeulen, Roy E. Stewart, Maria C. Bolling, André P Wolff
DOI: 10.1093/bjd/ljag072
Cited by: 0
References: 10

Abstract

We conducted a randomized, double-blind, placebo-controlled crossover trial of sublingual 10% tetrahydrocannabinol/5% cannabidiol in eight adults with epidermolysis bullosa and chronic pain. No significant change in pain affect occurred, but 75% reported ≥ 30% global pain reduction. Analgesic use halved during active treatment. Mild adverse events were common and larger trials are warranted.

Fields of Study & Subjects

Cannabis and Cannabinoid Research Pain Mechanisms and Treatments Skin and Cellular Biology Research

Publication details

Journal / source
British Journal of Dermatology
Volume
194
Issue
6
Pages
1170–1173
Publication date
25 February 2026
Language
EN